Notiretatug rezetecan
Antibody–drug conjugate
Evidence outlook · registrational
Urothelial Carcinoma: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2028-01-31.
Also in development:Non-Small Cell Lung Cancer · Phase 2HR+/HER2- Metastatic Breast Cancer · Phase 2Cervical Cancer · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06738251 NCT06738251 · Advanced Urothelial Carcinoma Registry: NCT06738251 | 3 | Progression-free Survival (PFS) (Up to approximately 1.5 years.); Overall Survival (OS) (Up to approximately 1.5 years and 2 years.) 2026-07 | In progress: primary completion was expected 1 Jul 2026; results not posted | not yet graded | link ↗ |
View 1 more trial
NEC-UC2 NCT07393542 · Locally Advanced or Metastatic Urothelial Carcinoma Registry: NCT07393542 | 3 | Progression-free survival(PFS), assessed by BICR (up to 50 months) 2028-01-31 | In progress: results expected 31 Jan 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Competitive landscape
Other Nectin-4 drugs
Enfortumab Vedotin, Sutantatug envedotin, Zelenectide pevedotin, IPH4502, LY4052031. Compare all 6 Nectin-4 drugs
5 other tracked programmes target this mechanism, 1 of them ahead of this one.
This drug's own stage for Cervical Cancer: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Notiretatug Rezetecan: this drug | Phase 3 | Antibody–drug conjugate | Nectin-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Jobevne (bevacizumab-Nwgd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Reliable signal | No reviewed efficacy summary in this indication | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Tisotumab Vedotin Humax-Tf-Adc (Tivdak) | Approved | Antibody–drug conjugate | Tissue Factor (TF) | Partial signal | NCT04697628: Overall Survival (From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum up to 25 months)): Tisotumab Vedotin 11.5 Months (95% CI 9.8 to 14.9) | Chemotherapy 9.5 Months (95% CI 7.9 to 10.7) NCT03438396: Percentage of Participants With Confirmed Objective Response (OR) as Assessed by the Independent Review Committee (IRC) (From Day 1 through IRC verified disease progression, initiation of new anticancer therapy, study withdrawal, or death, whichever occurred first (approximately 20 months)): Tisotumab Vedotin 23.8 Percentage of Participants (95% CI 15.9 to 33.3) | |
| Vegzelma (bevacizumab-Adcd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Zirabev (bevacizumab-Bvzr) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Cadonilimab | Phase 3 | Multispecific antibody | PD-1×CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Enlonstobart | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Famitinib | Phase 3 | Small molecule | c-Kit, VEGFR2 (KDR), PDGFRbeta, VEGFR3, FLT1, FLT3 | not yet graded | No reviewed efficacy summary in this indication | |
| Sacituzumab Tirumotecan | Phase 3 | Antibody–drug conjugate | TROP2 | not yet graded | No reviewed efficacy summary in this indication | |
| Sutantatug Envedotin | Phase 3 | Antibody–drug conjugate | Nectin-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Volrustomig | Phase 3 | Multispecific antibody | PD-1 x CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Camrelizumab | Phase 2/3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Balstilimab | Phase 2 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| ALE.P02 | Phase 1/2(overall) | Antibody–drug conjugate | Claudin-1 (CLDN1) | not yet graded | No reviewed efficacy summary in this indication | |
| GI-101A | Phase 1/2 | Protein / enzyme therapeutic | CTLA-4 / IL-2Rβγ | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(14 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Notiretatug rezetecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.